Posted 2 months ago

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)

ClinicalTrials.gov ID NCT06492616

Protocol number STML-ELA-0422

Sponsor Stemline Therapeutics, Inc.